ACE2 and COVID-19: Consequently, the possible impact of renin–angiotensin–aldosterone system (RAAS) inhibitors on COVID‐19‐related outcomes has emerged as a topic of interest2 and their mechanisms of action– in particular, the potential upregulation of angiotensin‐converting enzyme 2 (ACE2), which is associated with viral entry into bronchial cells.3